|
In the wake of increasing continuity billing practice complaints, the Federal Trade Commission ("FTC") is again taking a hard look at the space.
Category:
News and Media
On April 15, 2024, Fresenius Kabi announced the U.S. launch of its ACTEMRA biosimilar, TYENNE (tocilizumab-aazg) as an intravenous formulation.
Category:
News and Media
The potential mega merger would give BHP access to Anglo American's copper assets.
Category:
News and Media
All news |
||||||||||||||||||
|